Castle Biosciences Inc (CSTL) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
5 readings, 2 filed under bull and 3 under bear. Every figure is ours; the model chose the side.
the bull case· 2
175
managers reporting a position in thirteen F filings
13fJun 30 '26+6.18%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
44.00%
of revenue from the largest disclosed customer Medicare
10-Kfiled Feb 26 '2630
managers whose positions together make up four fifths of the reported value
13fJun 30 '269 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 5 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
Castle Biosciences Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Medical Laboratories
Prev close 35.53 · gapped above the open, never looked back. High/low 35.82 at 7:15 am ET, 35.82 at 7:15 am ET.
tall tick = annual report · 1 on record
175 managers report a position worth $653.8M between them, and 30 of them hold 80% of it.
Of the 6 companies Castle Biosciences Inc moves with most closely, 1 also shares its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 8071, Services-Medical Laboratories, from each company's own filings. Largest first.
A rule beside a ticker marks a company that appears in both readings.
Which of these the filings never mention ›CSTL (Castle Biosciences Inc) has 6 disclosed suppliers and 8 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: QGEN +0.15%, in industrials & materials.